Epidemiology and Clinical Features of Idiopathic Trigeminal Neuralgia and Glossopharyngeal Neuralgia: Similarities and Differences, Rochester, Minnesota, 1945-1984

Katusic, Slavica K.; Williams, David B.; Beard, Mary K.; Bergstralh, Erik J.; Kurland, Leonard T.

doi:10.1159/000110284

Cited by 327 publications

(155 citation statements)

References 8 publications

Supporting

Mentioning

144

Contrasting

Unclassified

Order By: Relevance

“…1 The annual incidence of TN is 4 to 5 in 100,000. 2 The latest classification of the International Headache Society 3 distinguishes between classic and symptomatic TN. Classic TN (CTN) includes all cases without an established etiology (i.e., idiopathic, as well as those with potential vascular compression of the fifth cranial nerve).…”

mentioning

confidence: 99%

Practice Parameter: The diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review)

Cruccu²,

et al. 2008

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Practice Parameter: The diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review)

Cruccu²,

et al. 2008

View full text Add to dashboard Cite

show abstract

“…It affects ~4.5 per 100,000 of the general population 1,2 , with onset usually in middle or old age; however, young adults, mainly those with multiple sclerosis, and even children may be affected. Attacks, usually lasting a few seconds, may occur repeatedly within a short period of time.…”

mentioning

confidence: 99%

Beneficial effects of botulinum toxin type A in trigeminal neuralgia

Zúñiga

Díaz

Piedimonte

et al. 2008

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

-Botulinum toxin has been thoroughly studied as a potential tool in the treatment of several pain syndromes. Therefore, we assessed the clinical effects of botulinum toxin type A injections in 12 patients with otherwise unresponsive idiopathic trigeminal neuralgia. Patients were infiltrated with 20-50 units of botulinum toxin in trigger zones. Those who presented with mandibular involvement were also infiltrated in the masseter muscle. The patients were assessed on a weekly basis using the Visual Analogic Scale for pain. Ten of our patients reported a significant benefit from botulinum toxin injections, with reduction or even disappearance of pain, and remained pain free for as long as 60 days. Our findings suggest that botulinum toxin may represent a useful therapeutic tool in the management of patients with this entity.Key wOrdS: trigeminal neuralgia, botulinum toxin, facial pain. Beneficio de la toxina botulínica tipo a en neuralgia del trigeminoResumen -La toxina botulínica ha sido estudiada en forma exhaustiva como una potencial herramienta en el tratamiento de múltiples síndromes dolorosos. Por lo tanto, evaluamos los efectos clínicos de la aplicación de toxina botulínica tipo A en 12 sujetos con neuralgia trigeminal idiopática resistente a manejo farmacológico. Se aplicaron en dichos sujetos entre 20 y 50 unidades de toxina botulínica tipo A en las zonas gatillo. Además se infiltró el músculo masetero en aquellos que presentaban involucro mandibular. Los sujetos fueron evaluados semanalmente con una escala visual análoga para dolor. diez de los sujetos reportaron un beneficio significativo con el uso de toxina botulínica, con reducción e incluso desaparición del dolor, permaneciendo libres de dolor por un periodo de hasta 60 días. Nuestros hallazgos sugieren que la toxina botulínica puede representar una herramienta terapéutica útil en el manejo de pacientes con esta entidad.PALABrAS-cLAVe: neuralgia trigeminal, toxina botulínica, dolor facial.

show abstract

“…1 It is an uncommon craniofacial pain syndrome, representing 0.2-1.3% of facial pain syndromes, with an annual incidence of 0.7 cases per 100,000 habitants per year according to a population-based study. [2][3][4] In some cases, it is associated with excessive vagal outflow; which leads to bradycardia, hypotension, syncope or cardiac arrest. [5][6][7] Dandy elucidated the pathophysiology of trigeminal neuralgia and proposed vascular compression at the root of the trigeminal nerve as the main etiology, causing demyelinization, and ephaptic transmission.…”

Section: Introductionmentioning

confidence: 99%

MVD for trigeminal neuralgia; neuralgia revisited with review of literature

Melkundi¹,

Melkundi²

2017

Int J Otorhinolaryngol Head Neck Surg

View full text Add to dashboard Cite

INTRODUCTIONTrigeminal neuralgia (TN) is a disorder characterized by sudden sharp, shooting, lancinating pain attacks lasting several seconds to several minutes and localized to one or two branches of the trigeminal nerve. These attacks may begin spontaneously or they can be initiated by stimulation of the so-called trigger zones. The classic episodes of shooting pain are interrupted by pain-free intervals with remissions occasionally lasting for years. 1It is an uncommon craniofacial pain syndrome, representing 0.2-1.3% of facial pain syndromes, with an annual incidence of 0.7 cases per 100,000 habitants per year according to a population-based study. [2][3][4] In some cases, it is associated with excessive vagal outflow; which leads to bradycardia, hypotension, syncope or cardiac arrest. [5][6][7] Dandy elucidated the pathophysiology of trigeminal neuralgia and proposed vascular compression at the root of the trigeminal nerve as the main etiology, causing demyelinization, and ephaptic transmission. 8,9 It is shown ABSTRACT Background: Trigeminal neuralgia (TN) s an uncommon facial pain syndrome. It is commonly characterized by sudden onset of an attack of intense electric shock like facial pain localized along the sensory distribution of the ninth cranial nerve. Although many patients respond to the medical line of treatment but when PTS symptoms become intractable and could not tolerate the medications have to go for surgical decompression. Our study aims to review about micro vascular decompression for trigeminal neuralgia and its outcome along with the review of literature. Methods: It is a retrospective study conducted on 40 cases who were diagnosed with TN. between the period of July 2009 to July 2015. MVD has been performed on all the patients. Demographic data, clinical presentation, surgical findings, complications and long term follow-up were reviewed. Results:The median age of onset of TN is 50.4 years divided into five age groups ranging from 24 to 89 years with female preponderance showing 65.5% as compared to males. The distribution of location was in the ratio of right to left is 1.5:1. There was no mortality is seen in the study. 3 patients among them study population had complications 3 patients had facial hyposthesia, 1 patient had V3 paresis and 1 patient had CSF otorrhoea which got settled with drainage LP. All the patients had satisfactory improvement except one patient who had persistent pain. Conclusions: To conclude micro vascular decompression (MVD) is the surgical procedure of choice for the treatment of medically refractory TN who is fit for surgery. Of all the currently available surgical methods MVD provides the highest rate of long term satisfaction for the patients and offers the lowest rate of pain recurrence.

show abstract

Epidemiology and Clinical Features of Idiopathic Trigeminal Neuralgia and Glossopharyngeal Neuralgia: Similarities and Differences, Rochester, Minnesota, 1945-1984

Cited by 327 publications

References 8 publications

Practice Parameter: The diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review)

Practice Parameter: The diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review)

Beneficial effects of botulinum toxin type A in trigeminal neuralgia

MVD for trigeminal neuralgia; neuralgia revisited with review of literature

Contact Info

Product

Resources

About